Cancer pharmacogenetics: Polymorphisms, pathways and beyond

被引:152
作者
Ulrich, CM [1 ]
Robien, K
McLeod, HL
机构
[1] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98109 USA
[2] Washington Univ, Dept Med, St Louis, MO 63130 USA
关键词
D O I
10.1038/nrc1233
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
cancer. Pharmacogenetics aims to use knowledge of these variations to 'tailor' therapy for improved response and reduced toxicity. Most research so far has focused on single polymorphisms. A more comprehensive approach to predict treatment response will be to consider genetic variation in entire biological and pharmacological pathways. Of particular relevance to cancer chemotherapy is folate metabolism, which is the target of methotrexate and 5-fluorouracil. Furthermore, efforts have begun to construct pathways of genes that have pharmacological relevance for individual chemotherapeutic agents. Together, these pathway strategies offer a higher likelihood of achieving the promise of genetically guided cancer therapy.
引用
收藏
页码:912 / 920
页数:9
相关论文
共 79 条
[1]  
ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720
[2]  
Ando Y, 2000, CANCER RES, V60, P6921
[3]   INHIBITION OF 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOTIDE TRANSFORMYLASE, ADENOSINE-DEAMINASE AND 5'-ADENYLATE DEAMINASE BY POLYGLUTAMATES OF METHOTREXATE AND OXIDIZED FOLATES AND BY 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOSIDE AND RIBOTIDE [J].
BAGGOTT, JE ;
VAUGHN, WH ;
HUDSON, BB .
BIOCHEMICAL JOURNAL, 1986, 236 (01) :193-200
[4]   Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage [J].
Blount, BC ;
Mack, MM ;
Wehr, CM ;
MacGregor, JT ;
Hiatt, RA ;
Wang, G ;
Wickramasinghe, SN ;
Everson, RB ;
Ames, BN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) :3290-3295
[5]   THRESHOLD METHOTREXATE CONCENTRATION FOR IN-VIVO INHIBITION OF DNA-SYNTHESIS IN NORMAL AND TUMOROUS TARGET TISSUES [J].
CHABNER, BA ;
YOUNG, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (08) :1804-1811
[6]   A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia [J].
Chango, A ;
Emery-Fillon, N ;
de Courcy, GP ;
Lambert, D ;
Pfister, M ;
Rosenblatt, DS ;
Nicolas, JP .
MOLECULAR GENETICS AND METABOLISM, 2000, 70 (04) :310-315
[7]  
Chen J, 1996, CANCER RES, V56, P4862
[8]   Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate [J].
Chiusolo, P ;
Reddiconto, G ;
Casorelli, I ;
Laurenti, L ;
Sorà, F ;
Mele, L ;
Annino, L ;
Leone, G ;
Sica, S .
ANNALS OF ONCOLOGY, 2002, 13 (12) :1915-1918
[9]  
CHU E, 1990, J BIOL CHEM, V265, P8470
[10]  
Chu E., 1996, CANC CHEMOTHERAPY BI, P109